



ΠΑΡΑΣΚΕΥΗ 29 ΣΕΠΤΕΜΒΡΙΟΥ 2017

11.50-12.00	Welcome and Chair Remarks V. Georgoulas
12.00-13.40	Session 1: Breast Cancer Chairpersons: N. Xenidis, D. Tryfonopoulos
12.00-12.15	Presenter 1: S. Kokkali <ul style="list-style-type: none">• Abstract ID: 1000 Title: MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy.• Abstract ID: 1001 Title: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18).
12.15-12.30	Presenter 2: S. Peroukidis <ul style="list-style-type: none">• Abstract ID: 1008 Title: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.• Abstract ID: 506 Title: Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
12.30-12.45	Presenter 3: F. Stavridi <ul style="list-style-type: none">• Abstract ID: 504 Title: Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer• Abstract ID: LBA500 Title: APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
12.45-13.00	Presenter 4: G. Lambrodimou <ul style="list-style-type: none">• Abstract ID: LBA4 Title: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).• Abstract ID: 501 Title: 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.
13.00-13.25	Discussant: D. Tryfonopoulos

13.20-13.40	Discussion
13.40-14.10	Educational Session: Chairpersons: G. Fountzilas, D. Pectasidis
	Presenter : Ch. Christodoulou
	<ul style="list-style-type: none"> Title: New Approaches in Triple Negative Breast Cancer: PARP Inhibitors and Beyond
14.10-15.15	Light lunch
15.15-16.20	Session 2: Malignant Melanoma Chairpersons: D. Bafaloukos, K. Kalbakis
15.15-15.30	Presenter 1: A. Laskarakis
	<ul style="list-style-type: none"> Abstract ID: 9504 Title: Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. Abstract ID: 9505 Title: Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).
15.30-15.45	Presenter 2: I. Dimitriadis
	<ul style="list-style-type: none"> Abstract ID: 9507 Title: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. Abstract ID: 9508 Title: A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).
15.45-16.05	Discussant: D. Bafaloukos
16.05-16.20	Discussion
16.20-17.25	Session 3: Genitourinary Cancer (Non-Prostate cancer) Chairpersons: A. Bamias, S. Xynogalos
16.20-16.35	Presenter: K. Koutsoukos
	<ul style="list-style-type: none"> Abstract: 4501 Title: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). Abstract: 4502 Title: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
16.35-16.50	Presenter: E. Ntouvelis

16.50-17.10	<ul style="list-style-type: none"> • Abstract: 4507 Title: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). • Abstract: 4508 Title: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. <p>Discussant: A. Bamias</p>
17.10-17.25	Discussion
17.25-18.00	Coffee Break
18.00-19.00	Session 4: Patient and Survivor Care Chairpersons: C. Kosmas, M. Trichas
18.00-18.15	<p>Presenter: K. Stouraiti</p> <ul style="list-style-type: none"> • Abstract ID: LBA10004 Title: SCORAD III: Randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). • Abstract ID: 10006 Title: American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).
18.15-18.30	<p>Presenter: A. Koulouris</p> <ul style="list-style-type: none"> • Abstract ID: LBA2 Title: Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. • Abstract ID: 10009 Title: FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.
18.30-19.00	Discussion
19.00-20.00	Session 5: Gastrointestinal (Colorectal) Cancer Chairpersons: Ch. Papadimitriou, A. Koumariou
19.00-19.15	<p>Presenter: A Tzouvaras</p> <ul style="list-style-type: none"> • Abstract ID: 3505 Title: Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). • Abstract ID: LBA1 Title: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
19.15-19.30	<p>: Presenter: N. Tsoukalas</p> <ul style="list-style-type: none"> • Abstract ID: 3507 Title: Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. • Abstract ID: 3503

	Title: Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).
19.30-19.45	Discussant: G. Papaxoinis
19.45-20.00	Discussion
20.00-20.50	Session 6: Gastrointestinal (Non-Colorectal) Cancer Chairpersons: N. Kentepozidis, Ch. Christofyllakis
20.00-20.20	Presenter: T. Bilidas <ul style="list-style-type: none"> • Abstract: 4001 Title: Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). • Abstract: 4006 Title: Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. • Abstract: 4014 Title: Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.
20.20-20.35	Discussant: A. Karampeazis
20.35-20.50	Discussion

Σ ΑΒΒΑΤΟ 30 Σ ΕΠΤΕΜΒΡΙΟΥ 2017

09.00-10.10	Session 7: Lung Cancer (1) Chairpersons: V. Georgoulas
09.00-09.20	Presenter 1: M. Bakogeorgos <ul style="list-style-type: none"> • Abstract ID: LBA9007 Title: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. • Abstract ID: LBA9004 Title: Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo). • Abstract ID: LBA9008 Title: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
09.20-09.35	Presenter 2: K. Rapti <ul style="list-style-type: none"> • Abstract ID: 8500 Title: Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIa (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT):

	<p>A randomized, Phase III trial (CTONG 1104).</p> <ul style="list-style-type: none"> Abstract ID: 9000 Title: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) \geq50% enrolled in KEYNOTE-024.
09.35-09.55	Discussant: Ch. Kosmas
09.55-10.10	Discussion
10.10-11.00	Session 8: Lung Cancer (2) Chairpersons: M. Vaslamatzis, P. Katsasounis
10.10-10.30	Presenter: D. Stefanou
	<ul style="list-style-type: none"> Abstract ID: 8503 Title: Nivolumab (nivo) \pm ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. Abstract ID: 8505 Title: Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study. Abstract ID: LBA8507 Title: Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
10.30-10.45	Discussant: N. Katirtzoglou
10.45-11.00	Discussion
11.00-12.10	Session 9: Genitourinary Cancer (Prostate cancer) Chairpersons: Ch. Kourousis, N. Androulakis
11.00-11.20	Presenter: E. Maragouli
	<ul style="list-style-type: none"> Abstract: LBA3 Title: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Abstract: 5002 Title: A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). Abstract: 5009 Title: Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer.
11.20-11.35	Presenter: Z. Zafeiriou <ul style="list-style-type: none"> Abstract: LBA5003 Title: Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476). Abstract: 5004 Title: A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

11.35-11.55	Discussant: E. Bournakis
11.55-12.10	Discussion
12.10-12.40	Coffee Break
12.40-13.25	Session 10: Sarcomas Chairpersons: N. Ziras, D. Tzaninis
12.40-12.55	Presenter: V. Ramfidis <ul style="list-style-type: none"> • Abstract ID: 11000 Title: Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas. • Abstract ID: 11001 Title: Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.
12.55-13.10	Discussant: D. Tzaninis
13.10-13.25	Discussion
13.25-14.00	Session 11: Developmental Therapeutics Chairpersons: A. Polyzos, E. Petinellis
13.25-13.45	Presenter: E. Kontopodis <ul style="list-style-type: none"> • Abstract ID:LBA2501 Title: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. • Abstract ID: 2505 Title: Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. • Abstract ID: 2508 Title: First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.
13.45-14.00	Discussion
14.00-15.00	Light lunch
15.00-16.10	Session 12 : Head and Neck Cancer Chairpersons : Ch. Panopoulos, D. Moraitis
15.00-15.15	Presenter : N Vardakis <ul style="list-style-type: none"> • Abstract ID: 6000 Title: Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. • Abstract ID: 6007 Title: Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.

15.15-15.35	<p>Presenter 2: P. Katsaounis</p> <ul style="list-style-type: none"> • Abstract ID: 6002 Title: A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT). • Abstract ID: 6005 Title: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. • Abstract ID: 6009 Title: Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
15.35-15.55	Discussant: A. Argiris
15.55-16.10	Discussion
16.10-17.35	<p>Session 13: Hematologic Malignancies - Lymphomas Chairpersons: A. Fassas, Th. Economopoulos</p>
16.10-16.25	<p>Presenter 1: A. Sfika</p> <ul style="list-style-type: none"> • Abstract ID: 7500 Title: First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. • Abstract ID: 7503 Title: A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).
16.25-16.40	<p>Presenter 2: E. Eleftherakis - Papaiakevou</p> <ul style="list-style-type: none"> • Abstract ID: 7506 Title: Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. • Abstract ID: 8005 Title: Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.
16.40-16.55	<p>Presenter 3: E. Kastiris</p> <ul style="list-style-type: none"> • Abstract ID: 8000 Title: Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. • Abstract ID: 8003 Title: Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
16.55-17.15	Discussant: P. Kanellou

17.15-17.35	Discussion
17.35-17.50	Coffee Break
17.50-19.00	Session 14: Gynecologic Cancer Chairpersons: Ch. Papadimitriou, E. Terzakis
17.50-18.10	Presenter: S. Stamatopoulou <ul style="list-style-type: none"> • Abstract ID:5501 Title: Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. • Abstract ID: 5502 Title: Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer. • Abstract ID: 5505 Title: A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.
18.10-18.25	Presenter : A. Boutis <ul style="list-style-type: none"> • Abstract ID:5506 Title: Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. • Abstract ID: 5508
18.25-18.45	Discussant: Ch. Papadimitriou
18.45-19.00	Discussion
19.00-19.30	Educational Session: IIC Chairpersons: A. Kotsakis, O. Tsitsilonis Presenter: N. Pistalmatzian <ul style="list-style-type: none"> • Title: Immuno Checkpoint Therapy Combinations with PARP or with Other Checkpoint Inhibitors in Ovarian Cancer
19.30-19.50	General Discussion
19.50-20.10	Closing Remarks